Janssen Research & Development, LLC

Cypress, California

Phase IIListed · JNJ

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

What changed

Phase I trial registered: A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants

Apr 2025Trial registeredApr 27, 2025Source filing (opens the source filing in a new tab)

Momentum

80no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE1 registered
May 30, 2023
Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
ClinicalTrials.gov · NCT05896683 (opens the source filing in a new tab)
Trial
PHASE1 registered
Aug 5, 2021
Healthy, Hepatic Impairment · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
ClinicalTrials.gov · NCT04960124 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jan 13, 2021
Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants
ClinicalTrials.gov · NCT04667052 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jul 1, 2020
Healthy, Colitis, Ulcerative · TERMINATED · sponsor: Janssen Research & Development, LLC · A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis
ClinicalTrials.gov · NCT04457960 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jan 9, 2020
Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of JNJ-70033093 and Digoxin in Healthy Participants
ClinicalTrials.gov · NCT04206488 (opens the source filing in a new tab)
Trial
PHASE2 registered
Nov 7, 2018
Autism Spectrum Disorder · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder
ClinicalTrials.gov · NCT03664232 (opens the source filing in a new tab)
Trial
PHASE1 registered
Aug 28, 2018
Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants
ClinicalTrials.gov · NCT03649997 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jul 11, 2018
Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants
ClinicalTrials.gov · NCT03581916 (opens the source filing in a new tab)
Trial
PHASE1 registered
Feb 9, 2018
Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions
ClinicalTrials.gov · NCT03438461 (opens the source filing in a new tab)
Trial
PHASE1 registered
Feb 26, 2016
Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine
ClinicalTrials.gov · NCT02846519 (opens the source filing in a new tab)
Trial
PHASE1 registered
Dec 1, 2015
Influenza A Virus · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation
ClinicalTrials.gov · NCT02659735 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 75%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.96{"reasons":["name similarity 100%","semantic similarity 85%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.95{"reasons":["name similarity 100%","semantic similarity 84%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.95{"reasons":["name similarity 100%","semantic similarity 83%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.95{"reasons":["name similarity 100%","semantic similarity 83%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.95{"reasons":["name similarity 100%","semantic similarity 83%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.94{"reasons":["name similarity 100%","semantic similarity 82%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.94{"reasons":["name similarity 100%","semantic similarity 81%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.94{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.93{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["name similarity 100%","shared principal investigator / founder","same city"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study of JNJ-70033093 and Digoxin in Healthy Participants
Mar 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of JNJ-70033093 and Digoxin in Healthy Participants
Mar 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants
Feb 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation
Feb 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
Feb 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE2 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered